Takeda Announces Approval of Two Innovative Drugs in China: Susoctocog Alfa and Teduglutide

On February 23, the official website of the National Medical Products Administration (NMPA) showed,TakedaUnder its umbrellaTwo Innovative DrugsRecombinant Antihemophilic Factor (Porcine Sequence) Obizur (Susoctocog alfa,Susoctocog alfaGLP-2 Analog Injection: TeduglutideE (Teduglutide) Approved for Marketing in China. Susoctocog AlfaApplicable toOn-demand treatment and control of bleeding episodes in adult patients with acquired hemophilia A.

TakedaPeptideUsed forTreatmentShort Bowel Syndrome (SBS)Adults and pediatric patients aged 1 year and above;Patients should only be considered after a period of intestinal adaptation, when their condition is stable and dependent on parenteral...Nutritional SupportUse this product for treatment while holding.。

Susoctocog alfa is structurally similar and sequentially homologous to human coagulation factor VIII (FVIII), and is not easily inactivated by anti-human FVIII autoantibodies, allowing it to replace human FVIII and exert a significant hemostatic effect. In a prospective, Phase II/III multicenter, open-label clinical trial, a total of 28 patients with acquired hemophilia A were enrolled, and 100% of the patients showed an evaluable response within 24 hours after administration (bleeding stopped or decreased). Of these, 94% (16/17) of the patients receivedrpFVIIIAs a first-line treatment. In addition, as a recombinant protein, susoctocog alfa reduces the risk of blood-borne pathogen transmission.

Tideglusib is currently the world's only approved drug that mimics naturalGlucagonTeduglutide, a GLP-2 (glucagon-like peptide-2) analog, is administered once daily via subcutaneous injection. It enhances nutrient absorption in the remaining intestine and reduces the frequency and volume of parenteral nutrition. The half-life of natural GLP-2 is only 7 minutes, while the half-life of Teduglutide is approximately 1.3 hours. In a pharmacodynamic study conducted on adults, Teduglutide was shown to improve the volume of fluid absorbed by the intestine.

TideglusibPeptideAs early as 2012 in the EUApproved, subsequently gaining approval in the United States and Japan for the treatment of adult SBS, later expanding its indications to include SBS patients aged 1 year and above, under the brand nameForGATTEX。

Disclaimer:

Within the articleFor reference only, not constituting investment advice. Investors who operate based on this information bear their own risks. The neutrality is maintained regarding the statements and viewpoints in the text, and no express or implied guarantees are provided concerning the accuracy, reliability, or completeness of the content included. Readers are advised to use it solely as a reference and assume full responsibility.At your service. The articles published in this official account are mainly for sharing. If there is any infringement, please contact us and we will delete it.